No connection

Search Results

QTI vs TCRX

QTI
QT Imaging Holdings, Inc.
BEARISH
Price
$6.93
Market Cap
$83.5M
Sector
Healthcare
AI Confidence
90%
TCRX
TScan Therapeutics, Inc.
BEARISH
Price
$1.43
Market Cap
$85.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
QTI
--
TCRX
--
Forward P/E
QTI
--
TCRX
-1.86
P/B Ratio
QTI
12.79
TCRX
0.66
P/S Ratio
QTI
4.41
TCRX
8.32
EV/EBITDA
QTI
-18.18
TCRX
-0.18

Profitability

Gross Margin
QTI
45.36%
TCRX
0.0%
Operating Margin
QTI
-8.46%
TCRX
-851.5%
Profit Margin
QTI
-111.4%
TCRX
0.0%
ROE
QTI
--
TCRX
-71.28%
ROA
QTI
-19.05%
TCRX
-27.88%

Growth

Revenue Growth
QTI
877.2%
TCRX
286.0%
Earnings Growth
QTI
--
TCRX
--

Financial Health

Debt/Equity
QTI
0.81
TCRX
0.76
Current Ratio
QTI
2.81
TCRX
8.41
Quick Ratio
QTI
2.07
TCRX
8.15

Dividends

Dividend Yield
QTI
--
TCRX
--
Payout Ratio
QTI
0.0%
TCRX
0.0%

AI Verdict

QTI BEARISH

The company exhibits critical financial weakness with a Piotroski F-Score of 1/9, indicating severe fundamental distress. Despite an extraordinary YoY revenue growth of 877.20%, the company remains deeply unprofitable with a profit margin of -111.40% and a history of massive earnings misses. Technical trends are overwhelmingly bearish, characterized by a 78.7% price collapse over the last six months. While short-term liquidity is stable, the combination of poor health scores and negative earnings progression suggests a high risk of further devaluation.

Strengths
Explosive YoY revenue growth of 877.20%
Strong gross margin of 45.36% indicating product value
Healthy short-term liquidity with a Current Ratio of 2.81
Risks
Critical fundamental health as evidenced by Piotroski F-Score of 1/9
Severe net losses with a profit margin of -111.40%
Catastrophic price performance (-95.3% over 5 years)
TCRX BEARISH

TCRX exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe financial distress across all measured categories. While the company maintains a strong liquidity position with a Current Ratio of 8.41, this is offset by a catastrophic operating margin of -851.50% and a 5-year price decline of 86.4%. The stock is currently a speculative binary play, where a massive disconnect exists between the fundamental health (extremely poor) and analyst price targets ($6.00).

Strengths
Exceptionally high liquidity (Current Ratio 8.41)
Significant YoY revenue growth of 286%
Recent trend of beating EPS estimates (3/4 last quarters)
Risks
Zero Piotroski F-Score indicating systemic financial weakness
Extreme operational inefficiency (Operating Margin -851.50%)
Negative ROE of -71.28% showing rapid equity erosion

Compare Another Pair

QTI vs TCRX: Head-to-Head Comparison

This page compares QT Imaging Holdings, Inc. (QTI) and TScan Therapeutics, Inc. (TCRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile